

# Index

---

- Abel, A.B. 196–7  
Abowd, J. 312  
absorptive capacity 116, 255, 267–8, 374  
Academic Medical Centers (AMCs) 84, 90–96, 127  
accelerator model 179, 180  
access to information, policies to increase 391–2  
access to knowledge, global 401, 407  
access to technology, provision of 377–8, 392, 406–7  
accountability 101, 138  
accounting standards 187  
Acemoglu, D. 311, 354  
ACME computing facility 93  
Acs, Z.J. 116, 225  
adjustment costs 171, 172, 179  
Adler, P. 344  
advanced manufacturing technologies (AMTs) 329, 331–2  
Advanced Technology Program (ATP) 100, 143  
adverse selection 122, 211  
Aerts, K. 211  
affiliation-based trust 349  
ageing populations 20  
Aghion, P. 44, 52, 61, 119, 184, 282, 283, 304, 305, 311, 312, 339, 405, 417  
agriculture  
    Common Agricultural Policy (CAP) 402  
    open source models applied to research in 342  
    R&D spending on 132, 133, 136, 137, 140  
    subsidies to 310  
Ahn, S. 289  
AIDS 165  
Akerlof, G.A. 173  
Alam, P. 174  
Alderson, M.J. 177  
Alfaro, L. 117  
Allen, R.C. 333  
Almus, M. 196, 204, 232  
altruism 344, 346, 349  
    involuntary 361  
American Association for the Advancement of Science 82, 139, 148  
American Cancer Society 95  
American Competitiveness Initiative 110  
American Medical Association 156  
Amin, A. 23  
Anand, B.N. 184  
‘angel’ investors 373  
Angell, M. 159  
anti-takeover amendments 175  
Anton, J.J. 174  
Apache 341  
applied research  
    Europe’s performance in 302  
    share of, by US agencies 136, 139, 140  
appropriability problem 52–4, 56–7, 193–4, 195, 371–2  
Arellano, M. 179  
arm’s length financing 176, 177, 184, 186  
Arora, A. 195  
ARPANET 141  
Arrow, K.J. 17, 50, 52, 56, 116, 131, 153, 154, 169, 193, 194, 195, 327, 371  
Arundel, A. 216, 218, 225, 329, 331  
Arvanitis, S. 239, 245, 246, 252, 255, 267, 268, 269, 273, 274  
asset-augmenting foreign R&D 249  
asset-exploiting foreign R&D 249  
asymmetric contribution 348, 353

- asymmetric information 173–4, 176, 178, 182, 184, 194, 196, 372–4, 392–3
- Atomic Energy Commission 95
- Audretsch, D. 103, 225
- Auerbach, A.J. 177–8
- Auerswald, P.E. 373
- Austria
- basic research expenditure 114, 115
  - productivity indicators 115
- AUTM 68, 154
- automated data collection 341
- Avnimelech, G. 381
- Baily, M. 117
- Bailyn, B. 97
- Baldwin, C.Y. 332, 339, 359, 360–61
- Baldwin, J. 295
- Bania, N. 120
- Bank of England 182
- Bank of Israel 382
- bankruptcy 175
- Baran, Paul 141
- Barcelona 3% target for R&D
- investment 307, 310, 311, 317, 401, 407, 414
- bariatric medicine 165
- Barro, R. 118
- Bartelsman, E. 289, 290, 291, 292, 293, 294, 295, 296, 297, 298
- basic research 113–20
- appropriability of 10, 15–16, 152–4, 156–8
  - definition of 119–20
  - economic views on 116–17
  - empirical pattern of 113–16
  - Europe's performance in 302
  - evaluating impact in terms of health outcomes 149–52, 154–6, 157, 158, 165–6
  - financing of 10, 110, 118–19
    - economic rationale for
      - NIH-funded basic research 148–58, 165–6
    - further issues for exploration 119
    - optimal amount of 117–18
    - share of, by US agencies 136, 139, 140
- Baum, C.F. 211
- Bayh–Dole Act (1980) 15, 68, 108, 143, 154, 275, 342, 353–4
- BBN 141
- Beckstead, D. 331, 332
- Belderbos, R. 221
- Bell, M. 25
- Bell Labs model 188
- Bénassy-Quéré, A. 118
- Benkler, Y. 333, 337, 339, 340, 342, 352, 354, 358, 359, 361
- Berg, Paul 92, 93
- Bergemann, D. 176
- Berkeley Software Design (BSD)
- license 353
- Berlin Academy 88
- Bernal, J.D. 89
- Betker, B.L. 177
- between-firm effect 297, 298, 299, 301
- Bhagat, S. 181, 187
- Bhattacharya, S. 174
- bibliometrics 103
- 'big box' retail format 300
- 'big push' strategy for development 60
- Binswanger, H.P. 17
- biochemistry 84, 91, 92, 93, 96
- bioinformatics 128, 342
- biology 235, 236, 243
- biomedical sciences
- breakthroughs from the realm of
    - physics 85–96, 127–8
  - economic rationale for NIH-funded
    - basic research 148–58, 165–6
    - open source models applied to 342
    - R&D expenditure on 81–4, 96, 128, 135, 140, 164
- 'Biotech Valley' 93
- biotechnology 40, 59, 75, 185, 234, 242, 268–9, 363
- Black, B.S. 186
- Blair, M.M. 176
- Blass, A.A. 176–7
- 'Blind Giant Quandary' 37, 42
- Bloch, Felix 94
- Bloom, N. 211, 316
- Blostrom, M. 372
- blue skies projects 56
- Blundell, R. 220
- Boeing 328
- Bohnet, I. 349
- Bohr, Niels 85

- Bolton, P. 184  
 Boone, J. 312  
 'bottom-up' principle for allocating funds 231, 234, 242, 272  
 Bougheas, S. 181  
 boundary layer 100–101  
 bounded rationality 8, 40  
 Bowles, S. 344, 351  
 Boyd, R. 344  
 Boyle, J. 342  
 Bozeman, B. 101, 245  
 Bragg, Lawrence 86–90, 96  
 Bragg, William 86, 87  
 Branscomb, L.M. 373  
 Braun, D. 97  
 Brazil, peer production in 343  
 Brenneis, D. 106  
 Bresnahan, T.F. 58, 59, 393  
 bridging organizations 40  
 broadband penetration 316, 377–8  
 Brown, A. 97  
 Brown, George 99  
 Brown, W. 181  
 Buckley, P.J. 261  
 budget constraints 73  
 budget federalism 309  
 Bulan, L.T. 211  
 Bush, V. 131, 135, 157, 163  
 Bush social contract 135, 138  
 business services 236  
 Butzen, R. 197
- Cabagnols, A. 221  
 CAD systems 329, 331–2  
 Cahuc, P. 312  
 Caliendo, M. 246  
 Cambridge University (UK) 85, 89; *see also* Cavendish Laboratory  
 Camerer, C.F. 344, 352, 354  
 Canada  
   entry size in 295  
   expenditure on mission-oriented R&D 133  
   expenditure on non-mission-oriented R&D 134, 135  
   percentage of population with university degree 82  
   survey of user-centered innovation in 331–2  
 Canadian Survey of Innovation 218  
 cancer treatment 95–6, 144, 165  
 Cantwell, J. 23, 249  
 capabilities development 25  
 capability accumulation, failures in 35, 40, 41  
 capital gains tax 178, 182  
 capital market imperfections 17, 181, 196  
 capital structure 176–7  
 carbon taxes 142  
 Cardenas, J.C. 344  
 cardiovascular disease 150–52, 158, 165–6  
 Carruth, A. 197, 211  
 Cassiman, B. 221  
 Casson, M.C. 261  
 catastrophes 67  
 catch-up, structural conditions necessary for 282, 311  
 Catozzella, A. 221  
 Cavendish Laboratory 85, 86–7, 89–90, 96, 127  
 Caves, R. 289  
 Cefis, E. 223  
 central coordination policies 40–41  
 Centre for European Economic Research 199  
 Centriano chip 384  
 CERN 140  
 channel neutrality 334  
 Chatterji, A.K. 330  
 chemical production processes 329–30  
 Chen, Z. 312  
 China  
   basic research expenditure 114, 115  
   productivity indicators 115  
 Cho, S. 175  
 Chubin, D. 106  
 Chung, K.H. 177  
 churning process 289, 290, 296, 318–19  
 Cimoli, M. 35  
 Clark, K.B. 332, 339, 359, 360–61  
 classical model of international trade and investment 248  
 client-led innovation services 289, 300  
 climate change 20, 29, 407; *see also* global warming  
 clinical trials 152, 158–9  
 Clinton, William Jefferson 146  
 cluster analysis 250, 252, 266

- cluster-oriented policies 269
- clustering 22–3, 59, 268
- co-payments 122–3
- Cockburn, I. 417
- Coe, D.T. 117, 372, 374
- Cohen, I. 103, 374
- Cohen, W.M. 26, 116, 195, 208, 255, 340
- Cohendet, P. 23
- Cold War 140, 144
- Cole, S. 103
- collaborative user-centered innovation
  - 332–3, 359, 405
  - conditions favorable to 333, 339
  - policies to support 333–5, 341, 362–4
- collateral 177, 178, 196, 392–3
- Colyvas, J. 97
- Comin, D. 386–7
- Commission of Technology and Innovation (CTI) coaching support programs 276
- Commission of Technology and Innovation (CTI) subsidies
  - ‘bottom-up’ principle of support 231, 234, 242
  - selection of projects 231
  - testing for impact on innovation 231–46
    - appendix 243–5
    - database 233–4, 243, 244
    - matched pairs analysis 231–2, 236–9
    - patterns of CTI promotion 234–6, 237
    - results 232, 239–42
    - summary and implications for Swiss technology policy 242–3
- Commission of the European Communities 29
- Common Agricultural Policy (CAP) 402
- Common Consolidated Tax Base 321
- common pool problems 55
- commons-based peer production
  - advantages of 339
  - applications other than software development 341–2
  - boundaries of 359–60
  - broader research agenda on systems design for cooperation 343–53
  - coexisting with proprietary production 362
  - commons-based production defined 337
  - conclusion 353–4
  - in context of patent and copyright systems 339–41
  - in developing economies 342–3
  - involuntary altruism or preferences for fairness? 360–62
  - motivations for 338–9
  - peer production defined 338, 359
  - policies to support 341, 362–4
  - see also* collaborative user-centered production
- commons-based production
  - definition of 337–8
  - see also* collaborative user-centered production; commons-based peer production
- communication 346, 347, 348
- Community Innovation Surveys 199, 215–25, 269
- direct use for innovation policy 216–19
- launch in Europe 215
- measures provided by 215–16
- purposes of 216
- questionnaires 218
- sampling procedure 218
- sources of innovation in 331, 359
- use to increase understanding of innovation 219–23
- complementarities in innovation strategies 221
- dynamics of innovation 223
- innovation policy 222–3
- R&D–innovation
  - output–productivity relationship 219–21
- Community Lisbon Program (CLP) 321, 322, 323
- Community Patent Regulation 321, 322
- Company Law Directive 321
- comparative advantage, sources of 20
- competence traps 35–6
- competition policy 113, 304, 320, 363

- competition versus cooperation 411–12  
 competitive analysis 25  
 competitiveness agenda 19–20  
 Competitiveness and Innovation  
   Framework Programme 307  
 complementary assets 39  
 computer industry 38, 41, 42, 66  
 computer literacy 389, 392  
 computer science 138, 139  
 computerized tomography (CT)  
   scanner 85, 94  
 conglomeration 62  
 Connell, D. 305  
 construction technology 235, 236, 243  
 contract theory 123  
 control rights 184, 185  
 convertible preferred securities 184  
 Conway, P. 300, 320  
 Cook-Deegan, R. 155  
 Cooke, P. 22  
 cooperation  
   definition of 345–6  
   versus competition 411–12  
   *see also* cooperation in R&D;  
     human cooperation, systems  
     design for  
 cooperation in R&D 258, 261, 263,  
   264, 268, 273  
 coordination failure 17, 20, 43, 50  
   positioning policy between responses  
     to coordination failure and  
     excess momentum 58–60  
   practical challenges of correcting  
     66–7  
 ‘copyleft’ protection 341, 353  
 copyright systems 63, 334, 340, 341,  
   363–4  
 Cornelli, F. 176  
 Cornish pumping engine 405  
 corporation tax 172, 178  
 corruption 387, 393  
 cost–benefit analysis 77  
 cost of cooperation 346, 348, 352, 361  
 cost reduction motive for foreign R&D  
   248, 249, 253, 265, 267  
 counterfactual method for evaluating  
   technology-based programs 103–4  
 Court of First Instance 363  
 CRAFT program 306  
 creative commons licenses 341  
 creative destruction 282, 283, 289–302,  
   318–20, 386, 401, 405  
   complementary structural policies to  
     improve 302–8, 320–23  
 Crépon, B. 219  
 Crick, Francis 86, 89  
 cross-catalysis 59  
 cross effect 297, 298, 299  
 crowding out 183, 196, 222, 347,  
   351–2, 354  
 Crowther, J.G. 88–9  
 Crowther, R.A. 97  
 CT scanner 85, 94  
 CTI Invest 276  
 CTI Start-up 276  
 cultural obstacles to innovation 304  
 Cutler, D.M. 150, 151, 152  
 cyclotron 97  
 Czarnitzki, D. 177, 195, 196, 198–9,  
   200, 202, 204, 206, 208, 211, 212,  
   232  
 Darby, M. 110  
 DARPA, *see* US Defense Advanced  
   Research Projects Agency  
   (DARPA)  
 Dasgupta, P. 52, 55, 413  
 data collection 108  
 Database Directive 341  
 David, P.A. 17, 21, 37, 42, 52, 55, 58,  
   62, 65, 68, 149, 183, 188, 196, 212,  
   404, 413  
 debt financing 177, 178, 181, 185, 186,  
   274  
 Deci, E.L. 350  
 decreasing marginal costs 52–3  
 defense  
   procurement programs 138–9, 140,  
     141, 145, 164  
   R&D spending on 132, 133, 135–8,  
     139, 143, 144  
   commercial spinoffs from 138,  
     140–41, 142  
 delayed vesting 184  
 Delgado, J. 306  
 Delphi studies 19  
 demand pull 220  
 demand-related policies 142  
 demonstration effects in the diffusion  
   of innovations 386–7

- Denmark, employment in small firms  
in 291
- depreciation 172, 178
- developed countries, innovation policy  
challenges in 401–2
- developing economies  
demand and innovation in 17
- diseases in 14–15, 377, 379
- goals of technology policy in  
17–18
- innovation policies in 368–70,  
374–9, 388–93, 397–8, 402,  
405–7
- access to information 391–2
- availability of finance 392–3
- incentives 390–91
- skills policies 389–90
- peer production in 342–3
- spillovers in 369, 374, 376, 385–8
- development spending, share of, in US  
136, 139
- Dewatripont, M. 184
- Dhrymes, P. 298
- Diamond v. Diehr* 153
- diffusion policies 35, 38, 40, 66–7
- Digital Millennium Copyright Act  
(DMCA) 334, 341, 363
- Directive on Services 306, 321
- discount rate, choice of 54
- disease-based criteria for NIH  
allocations 155–6
- diseases in developing countries 14–15,  
377, 379
- dividends, tax on 178
- Dixit, A.K. 194, 197
- DNA 87, 89, 90, 92, 93
- Doctors of Medicine (MDs) 90
- DOHA multilateral trade agreements  
321
- Doms, M. 286, 289, 298
- Donzé, L. 245
- Dosi, G. 23, 24, 35, 282, 302–3, 312,  
417
- Dresser, R. 160
- dual economy in Israel 382  
reasons for 383–5, 396–7
- Duguet, E. 196, 223
- Dunning, J.H. 249
- Dutch knowledge disease 404
- Dutka, A.B. 90
- dynamic capabilities 249
- dynamics of innovation 223
- early-stage technological development  
(ESTD), funding for 373–4
- EASDAQ 187
- EC-ENTR 316, 319
- ECFIN 315, 316
- econometric models 16, 100, 104–5
- economic performance, neoclassical  
and evolutionary conceptions of 8
- economic rents 57, 62, 63, 195; *see also*  
rent-seeking
- economic theory, role of, in technology  
policy analysis 15–16
- economic welfare, components of 281
- Edquist, C. 21
- education policy  
in developing economies 389–90  
and growth 113, 311  
*see also* tertiary education
- efficacy 346, 347, 349, 350
- Eichorst, W. 312
- Einstein, Albert 88
- EIS, *see* European Innovation  
Scoreboard (EIS)
- Eisenberg, R.S. 143, 153, 154, 157, 159
- electrical machinery/electronics 235,  
236, 243
- electronic microscopy 85
- electronics industry 43
- elementary particle physics 102
- Elkin-Koren, N. 341
- Ellickson, R.C. 350
- emergent properties 51
- emerging countries, innovation policy  
challenges in 402
- empathy 346, 347, 349
- employee stock ownership plan  
(ESOP) 175
- employment rate  
complementarity between  
productivity and 305–7  
in Europe 281, 315
- emulation 386, 406  
cost of 169  
and positive-sum norms 387–8
- Encaoua, D. 282, 304, 312, 315–16
- endogenous growth theory 311, 370,  
401–2, 405

- endoscopy 85  
 energy policy, European 304, 322  
 energy procurement programs 142  
 energy technology R&D 66–7, 132,  
   133, 136, 137, 407  
 energy use patterns 22  
 Eng, L. 175  
 Engel, D. 185  
 English language 389, 392  
 Enlightenment 387  
 Enos, J.L. 329  
 Enterprise Fund 182  
 entrepreneurial academic activity 91–2,  
   93  
 entrepreneurship, conditions for  
   413–14  
 entry effect 297, 298, 299  
 entry rate 294, 301  
 entry size 294–5, 301  
 entry to system, ease of 346, 348, 352  
 environmental policy 68  
 equilibrium feedback effects 119  
 equity financing 176–7, 178, 185, 186,  
   304, 306, 381  
 Ergas, H. 35, 41, 145  
 ESEE survey 224–5  
 EU Database Directive 341  
 EU Framework Programs 100, 101,  
   307, 407  
 EU Services Directive 306, 321  
 Euler equation 179–80  
 Europe  
   venture capital industry in 183, 184,  
   185  
   *see also* European Union  
 European Bank of Investment (EBI)  
   308  
 European Coal and Steel Community  
   402  
 European Commission 18, 97, 284,  
   289, 308, 312, 363  
 European Council 284, 304, 308, 310,  
   403  
 European Innovation Scoreboard  
   (EIS) 216, 217, 272, 316–17  
 European Institute of Technology 28  
 European internal market 292, 301,  
   304, 305, 321, 322  
 European paradox 302  
 European Parliament 306  
 European Patent Office 317  
 European Research Area 29  
 European technology gap 281–312,  
   315–23  
   basic statistics on 281–2  
   creative destruction process and 282,  
   283, 289–302, 318–20  
   diagnoses from literature 282  
   difficulties in formulating economic  
   policy recommendations 282–3  
   innovation deficit in EU 316–19  
   sectoral locus of 284–9  
   based on ICT usage 283, 284–6,  
   300–301, 316  
   based on patterns of innovation  
   283, 285, 286–9, 301  
   structural policies implications  
   complementary structural policies  
   to improve creative  
   destruction process 302–8,  
   320–23  
   implementation level 308–11  
 European Telecommunications  
   Standards Institute (ETSI) 38  
 European Union  
   employment rate in 281, 315  
   export market shares of 303  
   funding instruments 307  
   GDP growth in 315  
   heterogeneity within 282–3, 311  
   ICT firms located in 303  
   innovation surveys in, *see*  
   Community Innovation  
   Surveys  
   productivity differences between US  
   and, *see* European technology  
   gap  
   R&D investment in 307–8  
   shift from industrial policy to  
   ‘knowledge’ policy in 402–4  
   territorially based research  
   networking strategy of 407  
   world market shares in ICT sectors  
   303  
 Eurostat 215, 315  
 eurozone 281, 283, 310–11  
 evaluation of R&D programs 101–9,  
   122–5, 144, 145, 232  
 evergreening 13, 14  
 evolutionary biology 344, 349

- evolutionary theory
  - compared with neoclassical theory 7–12, 21, 74–5
  - econometric models and 16
  - evolutionary failures 34–9
  - and motives for innovation 22
  - pharmaceuticals technology policy in context of 15
  - role of variety in 21–2, 36–8
  - and STIG systems 47
- exit effect 297, 298, 299
- exit from system, ease of 346, 348, 352
- exit rate 294, 301
- expandability option 196, 197
- experimental economics 343–4, 349–50, 351, 352, 361
- exploration–exploitation trade-off 36
- export market shares 303
- export-oriented versus local market-oriented innovation 376–9, 383
- external capital, cost of, relative to internal funding 170
  - economic theory explaining 173–8
  - testing for financial constraints 178–82, 196
- external knowledge inputs 255, 257–8, 263, 264, 265
- external plausibility check 252
- externalities generated by R&D 8, 10, 15, 195
  - appropriability problem due to 54, 56–7, 193–4, 195, 371–2
  - in developing economies 369, 374, 376, 385–8
  - demonstration effects in the diffusion of innovation 386–7
  - emulation and positive-sum norms in historical perspective 387–8
  - post-innovation competition 385–6
- international research spillovers 116–17, 118, 372
- from mission-oriented R&D programs 135
- from open science 56–7
- welfare-enhancing effects of 153–4, 170, 193–4
- Fabrizio, K. 330
- FACS (fluorescence activated cell sorter) 93–4, 127
- fairness 346, 347, 349–50
- Falk, A. 351
- Fazzari, S.M. 179, 180
- Federal Department of Energy 95
- Fehr, E. 344, 350, 351, 353, 354
- Feller, I. 103, 107, 109, 110, 354
- Fier, A. 232
- Figueiredo, P.N. 29
- Financial Accounting Standards Board (FASB) 187
- financial constraints
  - on Swiss companies 274–6
  - testing for 178–82, 196
- financing gap 169–88, 194, 196, 371, 372–4, 392–3
- Finland, venture capital industry in 185
- firm demography 290–94, 301
- firm size
  - distribution in Europe and US 290–94, 301
  - and financial constraints 274
  - and foreign R&D 256–9, 261, 262, 263, 264, 265, 267–8
  - and propensity for innovation 267–8, 273
- fiscal competition 118
- Flamm, K.J. 17, 145
- flat panel display industry 22
- Fleming, D. 97
- flexi-security regime 306
- flexibility of public policy 41–2, 72
- Florida, R. 249
- flow cytometry 94
- fluorescence activated cell sorter (FACS) 93–4, 127
- Folini, M. 3
- Foray, D. 404, 416
- foreign direct investment (FDI)
  - spillovers from 117, 118, 372
  - see also* Swiss firms, foreign R&D strategies of
- Foster, L. 286, 289, 300
- Framework Programs 100, 101, 307, 407
- France
  - basic research expenditure 114, 115, 118



- cash flow effects on R&D in 180–81  
 central system coordination in 41  
 entry, exit and turnover in 294,  
   295–6, 299  
 expenditure on mission-oriented  
   R&D 133  
 expenditure on non-mission-oriented  
   R&D 134, 135  
 firm size distribution in 291, 293, 294  
 percentage of population with  
   university degree 82  
 productivity indicators 115
- Francis, J. 175  
 Franke, N. 328, 329, 332, 339  
 Franklin, Rosalind 87, 89  
 Fransman, M. 37  
*Frascati Manual* (OECD) 27, 132  
 free-riding 361  
 Freeman, C. 20, 329–30  
 Frey, B.S. 349, 352  
 Friend, I. 187  
 Frolich, N. 344  
 Frost, T.S. 249  
 funding gap 169–88, 194, 196, 371,  
   372–4, 392–3  
 Funk, M. 117  
 Fuss, C. 197
- Gächter, S. 351, 352  
 Galetovic, A. 184  
 Galileo 307  
 Gambardella, A. 416  
 Gambetta, D. 350  
 game theory 66, 77, 349, 360–61  
 Gamota, G. 103  
 Gassler, H. 110  
 gateway technologies 38  
 Gault, Fred 331  
 Gelijns, A. 90  
 gene-cultural co-evolution 344  
 GATT 402  
 General Agreement on Tariffs and  
   Trade (GATT) 402  
 General Public License (GPL) 341, 353  
 General Purpose Technologies (GPTs)  
   58–60  
   in developing economies 367, 369,  
   374–6  
 genetics 84, 91, 92, 93, 96  
 Georgiou, L. 245
- German Ministry for Education and  
 Research 73
- Germany  
 basic research expenditure 114, 115  
 biotechnology debate in 75  
 cash flow effects on R&D in 180, 181  
 entry, exit and turnover in 299  
 expenditure on mission-oriented  
   R&D 133  
 expenditure on non-mission-oriented  
   R&D 134, 135  
 firm size distribution in 291  
 government funding for start-up  
   firms in 182  
 matching methods used to evaluate  
   technology programs in 232  
 productivity indicators 115  
 scientific culture in 88  
 venture capital industry in 185
- Geroski, P. 223, 224, 295  
 Gersbach, H. 117, 118, 119, 120  
 Ghosal, V. 211  
 Ghosh, R.A. 338, 354, 406  
 Gibbons, M. 138  
 Gilson, R.J. 186  
 Gintis, H. 344, 351, 354, 361  
 Ginzberg, E. 90  
 Ginzton, E.L. 95, 97  
 Glennerster, R. 210  
 global division of labor 20  
 Global Summary Innovation Index  
   216–17  
 global warming 54; *see also* climate  
   change  
 globalization 344, 367, 376–7, 403–4,  
   409, 410, 411  
 GNU/Linux system 341  
 goals of technology policy 17–18,  
   412–15  
 Goel, R.K. 197–8  
 Goldberg, I. 394  
 Goldfarb, B. 97  
 Gompers, P.A. 185  
 González, X. 196, 225  
 Gordon, R. 281, 300  
 Gorecki, P. 295  
 Görg, H. 196, 232  
 governance of the commons 344  
 graduate students, role in innovation  
   108

- Granovetter, M.S. 23  
 Granstrand, O. 249, 251  
 granularity 333, 339, 352, 362  
 Greenberg, D. 156  
 Greenstein, S. 17  
 Griffith, R. 220, 304, 305, 311  
 Griliches, Z. 146, 170, 386  
*Grokster* decision 341  
 Gross, C.P. 155  
 gross turnover rates 295  
 Grossman, G.M. 370  
 growth policy 113  
 Guesnerie, R. 282, 304, 312  
 Guiso, L. 211  
 Guston, D.H. 135
- Hackett, E. 106  
 Hagedoorn, J. 29, 255  
 Haifa 384  
 Håkanson, L. 248, 250, 269  
 Hall, B.H. 17, 58, 170, 171, 174, 176,  
     178, 180–81, 183, 187, 194, 196,  
     206, 245  
 Hall, P.A. 29  
 Hamao, Y. 185–6  
 Harhoff, D. 180, 332, 416, 417  
 harmonization 412  
 Hart, J.A. 22  
 Harvard University 94  
 Haslam, S.A. 349  
 health
  - clinical research 152, 158–9
  - economic rationale for NIH-funded
    - basic research 148–58, 165–6
    - global solutions in area of 407
    - policies in developing countries 377
  - R&D spending on 133, 135, 136,  
     137, 139, 140, 142, 144, 164
  - see also* medical sciences
- health outcomes, impact of
  - NIH-funded basic research on  
 149–52, 154–6, 157, 158, 165–6
- Heckman, J.J. 238, 246  
 Heckscher, C. 344, 352  
 Hege, U. 176  
 Heidenreich, P. 150, 152, 159  
 Helper, S. 352  
 Helpman, E. 58, 117, 370, 374, 393  
 hemoglobin 86, 87, 89  
 Henrich, J. 354
- heresy 74, 75, 78  
 Herstatt, C. 329  
 Herzenberg, Leonard 93, 94, 97  
 Herzenberg, Leonore 93  
 Herzenberg Laboratory 93–4  
 high-risk research proposals 107  
 higher education, *see* tertiary education  
 Himmelberg, C.P. 178, 180  
 Hitler, Adolf 88  
 Hobijn, B. 386–7  
*Hochschulen* 88  
 Hodgkin, Dorothy 89  
 Hodgkin's disease 95–6  
 Hoffman-La Roche 272  
 Hollander, A. 304  
 Hollenstein, H. 217, 255, 258, 259, 261,  
     267  
 home-country effects of foreign R&D
  - direct effects 266–7
  - indirect effects from knowledge  
     spillovers 266, 267–8
- homophily 349  
 Hope, J.E. 354  
 Howitt, P. 52, 61, 119, 312, 405  
 Huber, R. 246  
 Huergo, E. 225  
 human capital
  - access to 249, 253, 263, 265, 266, 267
  - knowledge embedded in 171, 177
  - see also* skill shortages
- human capital intensity 255, 259, 268  
 human cooperation, systems design for  
 343–53  
 human genome, sequencing of 157  
 humanization 346, 347, 349  
 Hussinger, K. 196, 204  
 Hyytinen, A. 196
- Iammarino, S. 23  
 IBM 42, 384  
 ICQ 382  
 idiosyncratic competences 39  
 Ifo Institute for Economic Research  
 224  
 imitation 386, 406
  - cost of 169
  - and positive-sum norms 387–8
- imperfect capital markets 17, 181, 196  
 import substitution 60  
 inaction, dangers of 67–8

- incomplete contracts 184  
 incomplete markets 173  
 incubators 380  
 India 389  
 industrial dynamics 25, 27, 283,  
 289–302, 318–20  
   complementary structural policies to  
   improve 302–8, 320–23  
   in developing economies 386  
 industrial policy  
   in emerging countries 402  
   in Europe 303  
   shift from industrial to  
   ‘knowledge’ policy 402–4  
 Industrial Revolution 387  
 infant industry argument 17, 22  
 inflation rate 198  
 information, policies to increase access  
   to 391–2  
 information and communication  
   technologies (ICT)  
   adoption in developing economies  
   375–6, 377–8  
   CTI support for projects in 234, 235,  
   236, 243  
   development by commercial sector  
   128  
   development in Israel 379–85, 396–7  
   and global access to knowledge 401  
   government role in coordinating 66  
   to impart basic skills 389  
   location of top ICT firms 303  
   ‘mass customization’ provided by  
   377  
   R&D intensity of ICT firms 317–18  
   regulatory barriers and diffusion of  
   299–300, 320, 321  
   sectoral differences in usage of 283,  
   284–6, 300–301, 316  
   world market shares in 303  
 informational effects 386  
 initial public offerings (IPOs) 185–6,  
 381  
 innovation complementarities 50,  
 59–60, 369, 376, 383  
 innovation in innovation 404–5  
 innovation indicators 255, 256, 263,  
 264, 265, 316–17  
 innovation inputs 215, 255, 256, 263–4,  
 265, 317  
 innovation outputs 215, 255, 256, 263,  
 264, 265, 317  
   R&D–innovation  
   output–productivity  
   relationship 219–21  
 innovation surveys 215–25  
   direct use for innovation policy  
   216–19  
   launch in Europe 215  
   measures provided by 215–16  
   purposes of 216  
   questionnaires 218  
   sources of innovation in 331–2, 359  
   use to increase understanding of  
   innovation 219–23  
   complementarities in innovation  
   strategies 221  
   dynamics of innovation 223  
   innovation policy 222–3  
   R&D–innovation  
   output–productivity  
   relationship 219–21  
   *see also* Community Innovation  
   Surveys; Swiss Innovation  
   Survey  
 innovative firms, proximity to 249, 253,  
 263–4, 266  
 Institute of Medicine 148, 155  
 institutional failures 51  
 institutional investors 175, 275, 276  
 institutional mechanisms, evolution of  
 61–4  
 instrumental variables 179, 188  
 integrated circuits 139  
 integration policy 268  
 Intel 384  
 interdisciplinary research 84, 87, 96,  
 102, 106, 107, 127  
 interfaces, access to 334, 359, 362–3  
 internal financing of R&D 178, 187,  
 196, 274, 373  
 internal life of the firm 49  
 Internal Market Program 322  
 internalizing advantages (I-advantages)  
 249, 252, 261, 263, 264, 265  
 International Haplotype Mapping  
 project 342  
 international research spillovers  
 116–17, 118, 372  
 international trade liberalization 402

- Internet 375, 401  
 access in developing countries 377–8, 392  
 architecture of 65  
 communications cost reduced by 333, 361  
 development in US 140–41  
 government funding for access to 334  
 learning via 389  
 Internet browsers 363  
 intertemporal knowledge spillovers 52  
 investment in R&D  
 Barcelona 3% target for 307, 310, 311, 317, 401, 407, 414  
 characteristics of 170–71  
 costs of financing 169–88  
 government support for, *see* R&D subsidies  
 and innovation 28  
 under uncertainty 193–212  
 financing difficulties arising from 171, 173, 184, 194, 196  
 patent policies and 194–5, 198–9, 200, 202, 204–8, 209, 210  
 real options approach to 194–5, 198, 200, 202, 204, 205, 210  
 relationship between uncertainty and investment 196–8  
 subsidies and 194–5, 196, 198–9, 200–204, 208, 209, 210–11  
 involuntary altruism 361  
 Ireland  
 basic research expenditure 118  
 cash flow effects on R&D in 181  
 matching methods used to evaluate technology programs in 232  
 irreversible capital 194, 197, 198  
 Irvine Foundation 95  
 isotope tracer techniques 86  
 Israel, development of High Tech sector in 379–85, 396–7  
 accounting for dual economy 383–5, 396–7  
 innovation policies 379–81  
 outcomes 381–2, 396  
 Israeli Ministry of Industry and Trade 379–80  
 Italy, firm size distribution in 291  
 Jacobs, B. 312  
 Jacobsson, S. 182  
 Jaffe, A.B. 66, 107, 116, 149, 188  
 Japan  
 basic research expenditure 114, 115  
 cash flow effects on R&D in 181  
 catching-up policy in computer industry in 42  
 expenditure on mission-oriented R&D 133  
 expenditure on non-mission-oriented R&D 134  
 GDP growth 315  
 productivity indicators 115  
 publications in life sciences in 81  
 venture capital industry in 185–6  
 ‘vision’ of government policy in 37, 43  
 world market shares in ICT sectors 303  
 Jaumandreu, J. 225  
 Java 363  
 Jege, R. 352  
 Jensen, M.C. 174  
 Johnson, J. 360  
 Johnston, M.S. 175  
 Joint Technology Initiatives 28  
 Jones, C.I. 371  
 Jorgenson, D.W. 376  
 Kadiyala, S. 150, 151, 152  
 Kaplan, Harry 91, 92, 93, 94–5  
 Kaplan, S.N. 126, 184  
 Karaomerliolu, D.C. 182  
 Kealey, T. 116  
 Keller, W. 117  
 Kendrew, John 86  
 Keniston, K. 135  
 Kennedy Center for Molecular Medicine 92–3  
 Kennedy Foundation 92  
 Kevles, D.J. 95, 97  
 Kleinman, D.L. 157  
 Kleinrock, Leonard 141  
 Klette, T.J. 66, 188, 196, 245  
 Kline, S.J. 20–21  
 Klug, A. 97  
 knowledge, global access to 401, 407  
 ‘knowledge’ policy, move towards 402–4

- knowledge-seeking foreign R&D 248–9  
 knowledge transfer to headquarters  
     253, 263–4, 266–7  
 Kok, W. 282, 284, 308, 312  
 Kok High-Level Group report 308, 311  
 Kokko, A. 372  
 Konle-Seidl, R. 312  
 Kopeinig, S. 246  
 Kornberg, Arthur 92, 93  
 Kornberg, Roger 93  
 Kortum, S. 109, 185  
 Kraft, K. 177  
 Kremer, M. 210, 360  
 Kremp, E. 220  
 Kruger, Charles 97  
 Krugman, P. 407  
 Kuemmerle, W. 249  
 Kulatilaka, N. 211  
 Kuznets, S. 25–6  
 Kyoto Prize 94
- Labeaga, J.M. 221  
 labor market reform 304, 305, 306–7,  
     309, 311, 315, 320, 321, 322  
 Lach, S. 171, 196  
 Lachenmaier, S. 224  
 Lakhani, K. 354  
 Lamont, M. 106  
 Lang, H.H.P. 187  
 Langlois, R.N. 138  
 Lanjouw, J.O. 208  
 lasers 86  
 late industrialization 18  
 Laudel, G. 106  
 Le Bas, C. 221, 223, 249  
 lead times 39  
 lead users, innovations by 328  
 leadership 346, 348, 352–3  
 Leahy, J.V. 211  
 Leamer, E. 104  
 leapfrogging 18, 282, 311  
 learning failures 35, 40, 41  
 Lecuyer, C. 97  
 Lederberg, Joshua 92–3  
 Leiponen, A. 221  
 Leland, H.E. 173  
 ‘lemons’ premium 173–4, 177, 181, 184  
 Lenoir, T. 97  
 Lensink, R. 197, 211  
 Lerner, J. 182, 183, 185, 341, 354, 361
- Leslie, S.W. 140  
 Lettl, C. 330  
 leveraged buyout (LBO) 174, 176  
 Levin, R.C. 26, 39, 169, 340  
 Levinthal, D.A. 116, 374  
 licensing 15, 340–41, 353, 363  
 Licht, G. 196  
 Lichtenberg, F. 117, 139, 152, 155, 160  
 life sciences  
     breakthroughs from the realm of  
         physics 84–96, 127–8  
     publications in 81, 84  
     R&D expenditure on 81–4, 96, 128  
 Likert scales 106, 251, 253, 256, 258,  
     259, 261  
 linac technology 95  
 linear accelerators 86  
 linear model 19–20, 23  
 liquidation costs 177  
 liquidity constraints, testing for  
     178–82, 196  
 Lisbon Agenda 28–9, 216–17, 284,  
     307, 308, 310, 311, 315, 321–3,  
     403, 414  
 Lisbon Summit (2000) 281, 308, 321  
 Litan, R.E. 176  
 literacy 389  
 literature-based innovation indicators  
     225  
 loans for R&D 380  
 local market-oriented versus export-  
     oriented innovation 376–9, 383  
 localization studies 22–3  
 location-specific advantages  
     (L-advantages) 249  
 location-specific disadvantages  
     (L-disadvantages) 252, 260–61,  
     263, 264, 265  
 lock-in 21, 35–6, 50, 65  
 Loungani, P. 211  
 Lowen, R.S. 140  
 Lumme, A. 185  
 Lundvall, B.-Å. 20  
 Luria, Salvador 86  
 Lüthje, C. 328, 329
- Maccoby, M. 352  
 MacDuffie, J.P. 352  
 machinery and apparatus construction  
     234, 235, 236, 243

- macroeconomic growth models 47  
 macroeconomic policies 113  
 Magnet Program 380  
 magnetic resonance imaging (MRI) 86,  
   94, 127, 377  
 mainframes 41, 42  
 Mairesse, J. 187, 206, 220–21  
 Majewski, S.E. 185  
 Majumdar, S.K. 175  
 Malerba, F. 21, 35, 36, 44, 75, 76–7,  
   223, 362  
 Mallard, G. 106  
 management practices, quality of 316  
 Manly, B.F.J. 252  
 Mannheim Innovation Panel (MIP)  
   199  
 Mansfield, E. 152, 169, 327, 340, 386  
 Manufacturing Extension Partnership  
   (MEP) program 100  
 manufacturing sector  
   entry, exit and turnover in 294–9,  
     301–2  
   ICT usage in 284–6, 300–301  
   patterns of innovation in 285,  
     287–8, 301  
   size distribution of firms in 291–4,  
     301  
 Marburger, J. 101, 103  
 Marco, A.C. 211  
 marginal product of capital 172, 173,  
   179  
 marginal profit condition 172, 173, 179  
 marginal social rates of return 54, 57  
 market concentration 256, 259, 264  
 market growth, medium-run 255, 258,  
   263, 264, 265  
 market interest rate 179–80  
 market failure  
   appropriability problem and 52–4,  
     56, 193–4, 195, 371–2  
   and funding gap 170, 172, 186, 371,  
     372–4  
   and mission-oriented programs 131,  
     132, 135, 141, 142, 145, 163  
   neoclassical economics and 9–11  
   and public support of basic medical  
     research 152–4, 156, 157, 158,  
     165  
   and public support of clinical  
     research 159  
   uncertainty and 195, 210  
 market-oriented foreign R&D 248,  
   249, 253, 254, 264–5, 266  
 Marmet, D. 274  
 Martin, B.R. 99, 104, 145  
 Martinez-Ros, E. 221  
 Maskin, E. 55  
 Massachusetts Institute of Technology  
   (MIT) 141, 390  
 matched-pairs analysis 231–2, 236–9  
 material sciences 235, 236, 243  
 Matsuyama, K. 66  
 Maurer, S.M. 342  
 Mazzoleni, R. 108, 211  
 McClellan, M. 150, 152, 159  
 McGeary, M. 155  
 McGuckin, R. 312  
 McPherson, M. 349  
 Meckling, W. 174  
 medical device patents 330  
 Medical Research Council 84, 87, 89,  
   95  
 medical sciences  
   breakthroughs from the realm of  
     physics 85–96, 127–8  
   economic rationale for NIH-funded  
     basic research 148–58, 165–6  
   open source models applied to 342  
   R&D expenditure on 81–4, 96, 128,  
     135, 140, 164  
   *see also* health  
 MedTech program 231  
 Merger, R. 153  
 merit reviews 102, 105–7, 138, 144,  
   145, 155–6, 157  
 Metcalfe, S. 17, 33, 35  
 microelectronics 235, 236, 243  
*Microsoft* cases 363  
 microwave linear accelerators 95  
 Miller, M.H. 172  
 Minton, B.A. 211  
 Miravete, E. 221  
 mission-oriented R&D 17, 66–7  
   defining and measuring investment  
     in 132–8  
   economic effects of 138–41  
   economic rationale for NIH-funded  
     basic research 148–58, 165–6  
   economic rationale for NIH-funded  
     clinical research 158–9

- economic theory and 131–46, 163–4  
 policy implications 142–4  
 ‘mixed’ foreign R&D strategies 250,  
 253, 263–7  
 mobility of R&D personnel 97, 110,  
 193, 310, 323, 372, 390–91  
 modalities of innovation 215, 216  
 Mode 2 R&D 138  
 Modigliani, F. 172  
 Modigliani–Miller theorem 172–3  
 modularity 333, 339, 352, 359–60, 361,  
 362  
 Moed, H. 103  
 Moen, J. 66  
 Mohnen, P. 126, 221, 222  
 Mokyr, J. 369, 387  
 molecular biology 85, 86, 87, 92–3, 96,  
 127, 128  
 money 351–2  
 Monjon, S. 223  
 Monte Verità 1, 3  
 Moore, B. 185  
 Moore’s Law 375  
 moral hazard, financial difficulties  
 arising from 174–6, 182, 184, 393  
 Morange, M. 85, 86, 87, 88  
 Morgan, K. 22  
 Morrison, P.D. 329  
 mortality by cause of death 150, 151  
 Moses, H. 148  
 motives for innovation 22, 26–8, 76  
 Motorola 384  
 Mowery, D.C. 17, 27, 29, 36, 41, 67,  
 138, 140, 146, 154, 158, 207, 342,  
 416, 417  
 MRC Unit for the Study of Molecular  
 Structure of Biological Systems  
 (later Laboratory of Molecular  
 Biology) 89  
 Mulkay, B. 180  
 Muller, H.J. 86  
 multinational enterprises (MNEs) 217,  
 264, 269, 384, 403, 410–11  
 multiple imputation 252  
 Mundell, R.A. 248  
  
 NACE 202  
 Nagarajan, A. 175  
 nanotechnology 59, 63, 128, 234, 235,  
 236, 242, 243, 268–9  
 ‘Narrow Policy Window Paradox’ 37  
 Narula, R. 248, 249  
 NASA 93, 144  
 NASDAQ 187, 381  
 Nathan, D.G. 158  
 National Academies-Institute of  
 Medicine 102  
 National Academies-National  
 Research Council 102, 105, 106,  
 108  
 national champions 41, 403  
 National Institute of Standards and  
 Technology (NIST) 38  
 National Institutes of Health 148  
 allocation processes of 105, 106, 124,  
 154–7, 154–6  
 budget of 82–4, 144, 307  
 clinical research funded by 152,  
 158–9  
 economic effects of mission-oriented  
 spending by 142  
 economic rationale for NIH-funded  
 basic research 148–58, 165–6  
 funding metrics used by 101  
 grants for linac technology 95  
 impact on orientation of medical  
 schools 90  
 parent agency of 139  
 percentage of federally funded R&D  
 supplied by 140  
 public support for mission of 128  
 responsible for funding basic  
 biomedical research 12, 148  
 National Reform Programmes (NRPs)  
 308, 310, 321, 322, 323  
 National Research Council 141, 188  
 National Science Board 84, 120, 132,  
 133, 134, 136, 137  
 National Science Foundation (NSF)  
 97, 105, 109–10, 132, 135, 136,  
 137, 145, 334  
 national security 66, 141  
 National Semiconductors 384  
 national systems of innovation (NSI)  
 20–21, 75–6, 107–9, 138, 140, 145,  
 403–4  
 Nazi party 88  
 NBER, *The Rate and Direction of  
 Inventive Activity* (1962) 410,  
 414

- Nelson, R.R. 7, 9, 11, 17, 20, 29, 35, 36, 48, 50, 52, 108, 116, 131, 153, 154, 157, 158, 169, 193, 195, 211, 339, 390, 416
- neoclassical theory  
   compared with evolutionary theory 7–12, 74–5  
   econometric models and 16  
   and STIG systems 47
- NESTI/WPIA Innovation Microdata project 220
- net entry 294
- net entry effect 298, 301
- Netscape 363
- network externalities 60, 64–5, 362, 386
- neuroeconomics 344
- neuroscience 349
- ‘neutral’ government policies 379, 383
- new technology based firms (NTBFs) 21
- New York Times* 97
- niche technologies 29
- Nicoletti, G. 300, 320
- Nixon, Richard 144
- NMR spectroscopy 94
- Nobel, R. 248, 250
- Nobel Foundation 88
- Nobel Prize winners 86–7, 89, 92, 93, 94, 96, 97
- non-excludability 53, 116, 338, 359
- non-price competition, intensity of 255–6, 259, 264
- non-rival usage 10, 15, 52, 53, 116, 120, 169, 332, 359
- normative perspective 75–6, 77
- norms 346, 347, 350, 386  
   positive-sum 387–8
- North, Douglass 74
- Norway  
   basic research expenditure 114, 115  
   productivity indicators 115
- Novartis 272
- Novy-Marx, R. 194, 211
- Nowak, M.A. 344
- nuclear magnetic resonance (NMR) 94
- nuclear physics 89, 95, 140
- numeracy 389
- Nunan, C.S. 97
- Nurske, Ragnar 60
- Nuvolari, A. 405
- O’Mahony, M. 284, 285, 287, 288, 312
- O-ring technology 360
- O’Sullivan, M. 317
- OCM mechanism 308, 309, 310
- OECD, *see* Organization for Economic Co-operation and Development (OECD)
- off-patent drugs 159
- Office of Management and Budget’s Performance Assessment Rating Tool (PART) 101–2
- Office of Science and Technology Policy 103
- oil refining 329
- OLI paradigm 249, 250, 251, 252, 253, 255
- oligopoly 385–6
- open archiving and libraries 342
- open interfaces 334, 359, 362–3
- open method of coordination (OCM) 308, 309, 310
- open science regime 56–7, 342  
   co-existence with proprietary R&D regime 57–8
- open scientific publication 342
- open source educational materials 342
- open source software innovation 337, 352, 405  
   advantages of 332–3, 339  
   co-existing with proprietary production 362  
   in developing nations 342–3  
   ecological effects of patents on 340–41  
   features of 359–60  
   leadership emphasized in study of 352–3  
   licensing of 341  
   motivations for 338–9  
   policy questions 362–4
- open standards 334
- Opler, T.C. 176
- Oppenheimer, J.A. 344
- opportunistic capture 19, 62, 75–6
- optimal number of R&D personnel 412–13
- option value 194, 198, 210, 360, 361
- options-theoretic approach 68
- Organization for Economic Co-operation and Development



- (OECD) 48, 81, 102, 114, 119–20, 131, 142, 163, 182, 197, 220, 245, 268, 298, 321, 322, 383, 403
- Frascati Manual* 27, 132
- Oslo Manual* 27, 215, 224
- organizational culture 64
- organizational design 63
- organizational innovative services 289
- organizational psychology 349
- organizational sociology 349, 352
- 'orphan' drugs 14
- Orsenigo, L. 223
- Oslo Manual* (OECD) 27, 215, 224
- ostracism 344
- Ostrom, E. 344, 350, 354
- Owen-Smith, J. 58, 342
- ownership-specific advantages (O-advantages) 249, 252, 255–9, 263–4, 264, 265
- packet switching 141
- Pakes, A. 195
- Palo Alto 91, 94, 95
- Panofsky, Wolfgang 95
- Papanastassiou, M. 249
- Pareto distribution 171
- Pareto optimality 9–10
- Parigi, G. 211
- partial equilibrium analysis 109, 123
- Patel, P. 249
- patent applications in the EU 317
- patent citation analysis 103
- patent protection
  - for basic research 10, 15–16, 153–4, 156–8
  - changes to system 64, 68, 143, 153, 154
  - for clinical trials data 159
  - and collaborative user innovation 334–5
  - for commercial products 10
  - commons-based peer production in context of 339–41
  - in developing countries 390
  - effectiveness in appropriating returns 57, 153–4, 157–8, 194, 195, 372
  - and effects of uncertainty on R&D investment 194–5, 198–9, 200, 202, 204–8, 209, 210
  - European 306, 321, 322
  - evolution of system of 63, 64
  - excessive amount of 412
  - link with innovation 26–7, 38–9, 77, 177
  - for pharmaceutical companies 13–15
  - technology trajectories indicated by 24, 25
  - welfare losses from 57, 153–4, 158
- patent races 55
- patents filed by Israeli inventors 382
- patents filed by user-inventors 330
- path-dependency 21, 37, 48–9, 50
- patterns of innovation, sectoral differences in 283, 285, 286–9, 301
- Pavitt, K. 25, 42, 283, 285, 286, 287, 330
- Pearce, R.D. 249
- pecuniary externalities 309–10
- peer production, *see* commons-based peer production; *see also* collaborative user-centered innovation
- peer reviews 102, 105–7, 138, 144, 145, 155–6, 157
- Peeters, C. 187
- pension funds 175, 275, 276
- pension rights 321
- performance measurement 101
- Pernías, J. 221
- Perotti, E.C. 211
- persistence in innovation 223
- personal computers 42
- personal income tax 178
- Perutz, Max 86, 87–8, 89
- Peters, B. 223
- Petersen, B.C. 178, 180
- pharmaceuticals 12–15, 152
- Phelps, E. 304, 312
- Philips, D. 89, 90
- physical capital investment under uncertainty 211
- physical sciences
  - breakthroughs from the realm of 84–96, 127–8
  - R&D expenditure on 81, 83, 144
- Pindyck, R.S. 194, 197, 211
- Pisani-Ferry, J. 310, 312
- Pisano, I. 249

- Piscitello, L. 249  
 planetary biology 93  
 Pointner, W. 232  
 policy complementarities 123, 131, 142, 145, 217, 222–3, 283, 284, 302–8  
 political economy of science and innovation policies 73–4, 124  
 political science 344  
 Popper, Karl 19–20  
 Portugal  
   basic research expenditure 114, 115  
   productivity indicators 115  
 positive-sum norms 387–8  
*post-hoc ergo propter hoc* fallacy 150  
 post-innovation competition 385–6  
 Postel-Vinay, F. 312  
 Powell, W.W. 23, 58, 97, 342  
 pragmatism 74–5, 77  
 Prencipe, A. 27  
 price competition, intensity of 256–7, 258, 264, 265, 385–6  
 principal–agent problem 174–5, 176, 178  
 prisoner's dilemma 352  
 private foundations 56  
 private–public partnerships 231, 276, 302, 306, 307–8  
 probit estimation 238, 244–5  
 process engineering 235, 236, 243  
 process innovations 220, 221, 239, 240, 241, 285, 329–30, 368, 369, 383, 385  
 procurement 17, 36, 138–42, 145, 163, 164, 276, 306, 322, 342–3  
 producers model of innovation 327  
 product innovations 220, 221, 368, 369, 383, 385  
 product life cycles 25  
 production/management concepts 235, 236, 243  
 productivity  
   complementarity between  
     employment rate and 305–7  
     link between foreign R&D and 256, 259, 263, 264, 265  
     link between R&D and 219–20  
   productivity gap between Europe and US, *see* European technology gap  
   professional qualifications, recognition of 321  
   profit maximization 22, 179, 193, 210  
   profits from innovation, distribution of 171  
   proprietary R&D regime 57  
     co-existence with open science regime 57–8  
   ‘proximity’, elements of 22–3  
 public goods 8  
   advantages of revealing innovation as 332–3  
   basic research as a public good 116–17, 118–19  
   peer system as a game of private provision of 360–61  
   research as a public good 10, 52–4, 56  
 public health insurance 12–13  
 Public Health Service grants 92  
 public infrastructure, financing of 118  
 Public Library of Science 342  
 public–private partnerships 231, 276, 302, 306, 307–8  
 public procurement 17, 36, 138–42, 145, 163, 164, 276, 306, 322, 342–3  
 public utilities, regulatory framework for 304  
 Pugh, W.N. 175  
 punishment/reward 344, 346, 347, 350, 351  
 Purcell, E.M. 94  
 purchase precommitments 210  
 quality circles 344  
 quantum theory 85  
 R&D personnel  
   mobility of 97, 110, 193, 310, 323, 372, 390–91  
   optimal number of 412–13  
 R&D prizes 210  
 R&D subsidies 54  
   complementarity with other policies 60–64  
   crowding out effects of 183, 196, 222  
   design and implementation problems 196  
   economic rationale for 370–74, 378–9, 410

- and effects of uncertainty on R&D investment 194–5, 196, 198–9, 200–204, 208, 209, 210–11
- evaluation of subsidy programs 101–9, 122–5, 144, 145, 232
- focused programs 58–60
- and foreign R&D 260, 261, 263
- generic guidelines for public policy action 54–8
- impact of Commission of Technology and Innovation (CTI) subsidies 231–46
- innovation surveys containing information on 222
- for start-ups 182–3, 187
- Swiss system of 272, 275
- radiology 85, 95
- radiotherapy 94–6
- Rai, A. 153, 154, 342
- Rajan, R.G. 186
- Ram, R. 197–8
- Rammer, C. 232
- RAND Corporation 141
- Rao, R.P. 175
- Rate and Direction of Inventive Activity, The* (NBER, 1962) 410, 414
- rational behavior
  - alternative conceptions of 8, 22
  - behavioral deviations from 343
  - compatible with social preferences 361–2
  - see also* selfish rational actor model
- Rausch, L.M. 184
- Raymond, Eric 339
- Raymond, W. 223, 225
- real interest rates 176, 198
- real options approach to investment under uncertainty 194–5, 198, 200, 202, 204, 205, 210
- reciprocity 344
- recognition 349
- redeployable assets 177
- Reeve, N. 100
- regional innovation systems 22–3
- regulatory restrictions 260, 261, 263, 268–9, 274, 275, 299–300, 318–20
- relationship financing 176
- relativity theory 88
- rent-seeking 387–8
- Republic of Science 413
- reputation 333, 346, 348, 352, 361
- research budgets 125
- Research Joint Ventures (RJVs) 359
- research portfolios 55
- research priorities, setting of 103–5
- research universities 63, 64
- retail trade sector 286, 289, 293, 295, 299–300, 307, 316, 375
- Rettig, R. 155
- reverse equivalents 153
- reversibility option 196–7
- Richerson, P.J. 344
- Rilling, J.K. 349
- risk aversion 17, 174–5, 198, 276, 401, 405
- Ritter, J.R. 174
- RNA polymerase 93
- Robinson, J. 125
- Robson, M. 224
- Rockefeller Foundation 88, 89, 92
- Rockenbach, B. 351
- rodeo kayak industry 359
- Roessner, D. 245
- Roller, L.H. 126, 222
- Romer, P.M. 52, 370
- Ronstadt, R.C. 269
- Röntgen, Wilhelm 85
- Rosenbaum, B.R. 238
- Rosenberg, N. 20–21, 24, 90, 97, 139, 369, 390, 416
- Rottmann, H. 224
- routines 62, 64
- Rowen, H. 97
- royalties 340
- Rubin, D.B. 238, 252
- Rutherford, Ernest 87, 88, 89
- Ruttan, V.W. 17
- Ryan, R.M. 350
- Sabourin, D. 331, 332
- Sah, R.K. 63
- Sajeve, M. 216
- Sala-i-Martin, X. 118
- Sally, D. 348
- Salter, A. 99, 104
- Sampat, B. 152, 207
- San Francisco 91, 94
- Sapir, A. 282, 310, 312
- Sapolsky, H. 156

- Sarewitz, D. 101
- Saxenian, A. 22
- SBIR program, *see* Small Business Innovation Research (SBIR) program
- scale-intensive industries 285, 287
- Scarpetta, S. 300, 320
- Schankerman, M. 171, 208
- Schechter, A.N. 158
- Schelling coordination norms 350
- Scherer, F.M. 171
- Schmidt, K. 350
- Schneider, M. 119
- Schneller, O. 120
- Schot, J. 29
- Schrand, S. 211
- Schrödinger, E. 85
- Schumpeter, J.A. 8, 169, 170, 327, 396, 404
- Schumpeterian growth models 118, 396
- science and engineering graduates, number of 317
- Science and Policy Research Unit (SPRU) 224
- science and technology policy cycle 102
- science-based industries 285, 288
- science policy 268
- scientific instrument innovations 330
- scientific publications
- in life sciences 81, 96
  - open scientific publication 342
  - reputation effect of 361
  - technology trajectories indicated by 24, 25
- Scotchmer, S. 195, 340
- secrecy 39, 353
- sectoral systems of innovation 21
- misrepresentation of 42
- selection mechanisms for federal research funding 105–7
- selection–variety trade-off 36–8
- self-financing of R&D 178, 187, 196, 274, 373
- selfish rational actor model 343, 349, 351, 353, 361
- semiconductors 24–5, 38, 141, 145, 330, 402–3
- service sector
- CTI subsidies to 236, 245
  - entry, exit and turnover in 295, 299–300
  - ICT usage in 284–5, 286, 300, 316
  - innovation potential in 273
  - liberalization of 289, 304, 306–7, 310, 311, 320, 321, 322, 323
  - patterns of innovation in 285, 288–9
  - size distribution of firms in 293
  - setting research priorities 103–5
- Shackell, M. 175
- Shafaeddin, M. 17
- Shah, S. 329, 330, 332
- Shirky, C. 345
- Sierra, C. 249
- Silicon Valley 27, 93
- Simcoe, T. 140
- Simon, H. 8
- simulation models 44, 51, 68–9, 123–4
- single platform monopoly 362–3
- situational construal 349
- skill shortages 35, 260, 261, 263, 264, 274
- measures to address 35, 36, 268, 282, 389–90
- Slashdot 337, 338
- small and medium-sized enterprises (SMEs)
- financial constraints facing 274–5
  - innovation surveys covering 216
  - innovative capacity of 267–8, 273, 288
  - share of employment accounted for by 291, 301
  - support for 28, 35, 143–4, 182–3, 236, 242, 276, 288, 305–6, 308
- Small Business Innovation Research (SBIR) program 143–4, 182, 183, 305
- Small Business Investment Company (SBIC) program 182
- Smith, A. 175
- Smith, J. 246
- Sober, E. 344
- social network theory 349
- social preferences 361–2
- social rate of return to R&D 99, 153, 170, 193–4, 196, 210, 211, 327, 371–2, 410

- social returns from NIH-funded basic research 149–52, 154–6, 157, 158, 165–6
- social software 345, 350, 352
- socio-economic policy, innovations in 412
- Soete, L. 18, 207, 406, 410, 416
- software licensing 341, 353
- software patents 340–41
- solid-state physics 86, 390
- solidarity 346, 347, 349
- Solow, R. 330, 370
- Sonntag, V. 329, 331
- Soskice, D.W. 29
- South Korea
  - expenditure on mission-oriented R&D 133
  - expenditure on non-mission-oriented R&D 134
  - high-tech investments in 398
- Soviet Union, immigration from 380, 381
- space exploration, R&D spending on 132, 133, 136, 137
- Spanish Ministry of Industry 224–5
- specialized suppliers 285, 287–8, 289
- spectroscopies 86
- Sperling, G. 101
- spillover method for evaluating technology-based programs 103, 104
- spillovers, *see* externalities generated by R&D
- spinoffs 138, 140–41, 142, 163, 164
- Spivack, R.N. 188
- sporting equipment, innovations in 329, 330
- Stallman, Richard 341
- Stamper, M. 107
- standards 17, 38, 40
  - accounting 187
- standards-writing 334
- Stanford Historical Society 96
- Stanford Medical School 91–6
- Stanford University 91
- star scientists 108
- start-up firms
  - coaching support for 276
  - financial constraints facing 274–6
  - government funding for 182–3, 187
- State Aid for R&D and risk capital 321
- Statistics Canada 331–2
- Steinmueller, W.E. 18, 49, 76, 416
- Stern, N. 54
- Stern Report 54
- STIG systems 46–70
- Stigler, G. 2
- Stiglitz, J.E. 63
- stock markets 186, 187, 306
- Stokes, D. 148
- Strickland, S.P. 148, 149, 155, 156
- Strobl, E. 196, 232
- Strömberg, P. 126, 184
- Structural Funds 307
- subsidy quotient 232, 239, 242
- SUMEX computing facility 93
- sunk costs 177, 194
- supplier-dominated industries 285, 287
- supplier-dominated services 288–9
- surgical instruments patents 330
- survival rates 296, 301
- sustainable development 407
- Sweden
  - government funding for start-up firms in 182
  - percentage of population with university degree 82
- Swiss Federal Institute of Technology, Zurich (KOF ETHZ) 274
- Swiss firms, foreign R&D strategies of 248–69
  - hypothetical motives for foreign R&D 248–50
  - identifying foreign R&D strategies 250–51
    - data 251–2
    - empirical results 253–6
    - method 252
  - implications for economic policy in Switzerland 266–9
  - increasing internationalization of Swiss firms' R&D 248, 251
- Swiss Innovation Survey 232, 233, 237, 250, 251, 254, 256, 258, 259, 261, 262
- Swiss Institute for Business Cycle Research 273–4
- Switzerland
  - basic research expenditure 114, 115

- CTI coaching support programs in 276
- distinguishing characteristics of 272–3
- financing of innovation in 273–6
- impact of Commission of Technology and Innovation (CTI) subsidies in 231–46
- intellectual property rights in 275
- productivity indicators 115
- public procurement in 276
- R&D expenditure as share of GDP 272
- see also* Swiss firms, foreign R&D strategies of
- synthetic biology 59
- system dynamics theory 67
- systemic dysfunction 21
- systems of innovation 11, 16
- European Research Area and 29
- national systems of innovation (NSI) 20–21, 75–6, 107–9, 138, 140, 145, 403–4
- in pharmaceuticals 12, 15
- regional innovation systems 22–3
- sectoral systems of innovation 21
- misrepresentation of 42
- system failures 399–41, 75–6
- Szewczyk, S.H. 174
- Tabellini, G. 309
- tacit knowledge 40, 171, 261
- Taiwan, high-tech investments in 398
- Tassey, G. 17
- tax treatment of R&D
- financial bottlenecks caused by 274, 275, 276
- and foreign R&D 260, 261, 263, 269
- and variations in the cost of capital 172, 177–8, 181–2, 187
- team production 344
- technological frontier, distance from 113, 115, 118, 305, 311, 320
- technological innovation, definition of 3
- technological opportunity 34–5, 255, 258, 263, 264, 265
- technological paradigms 24
- technology paths, *see* technology trajectories
- technology push 220
- Technology Reinvestment Program 146
- technology trajectories 23–6, 33, 58, 69, 125, 330
- technology transfer 19–20, 94, 266, 268, 406
- Teece, D.J. 249
- telecommunications industry 38, 303
- Terman, Fred 91–3
- tertiary education 268, 302, 304, 310, 311, 317, 320, 323
- Tenbal, M. 381
- Thomas, J.M. 89, 90
- Thomson, J.J. 89
- timing of interventions 65–6
- Tirole, J. 184, 341, 354, 361
- Titman, S. 176
- Toivanen, O. 196
- Toole, A.A. 152, 196, 198–9, 200, 202, 204, 208, 211, 212
- TopNano21 program 231
- total factor productivity (TFP) growth 298–9, 370, 382, 383
- total quality management (TQM) 344
- tournament-like pay-off structures 55
- trade, spillovers from 372
- trademarks 75, 317
- Trajtenberg, M. 58, 206, 393
- transaction costs 261, 333–5, 339, 340, 360, 362, 405
- transistors 390
- transparency 346, 348, 352
- treatment effect 238
- TRIPS (Trade-Related Intellectual Property Rights) 13
- trucking 337
- trust 53, 345, 346, 347, 349, 350, 351, 352
- Tsai, A. 185
- Turner, J. 144
- Ueda, M. 185
- UK Ministry of Health 95
- unbounded expansibility 52
- uncertainty, physical capital investment under 211
- uncertainty, R&D investment under 193–212
- financing difficulties arising from 171, 173, 184, 194, 196

- patent policies and 194–5, 198–9, 200, 202, 204–8, 209, 210
- real options approach to 194–5, 198, 200, 202, 204, 205, 210
- relationship between uncertainty and investment 196–8
- subsidies and 194–5, 196, 198–9, 200–204, 208, 209, 210–11
- unintended consequences of
  - technology policies 34, 69
- unit of analysis for policy formation 409–11
- United Kingdom
  - cash flow effects on R&D in 180, 181
  - entry, exit and turnover in 299
  - expenditure on mission-oriented R&D 133
  - expenditure on non-mission-oriented R&D 134, 135
  - firm size distribution in 291
  - government funding for start-up firms in 182
  - percentage of population with university degree 82
  - publications in life sciences in 81, 84, 96
  - R&D expenditure on biomedical research 84
  - tax treatment of R&D in 182
  - venture capital industry in 185
- United States
  - Academic Medical Centers (AMCs) in 84, 90–96, 127
  - basic research expenditure 114, 115, 116
  - cash flow effects on R&D in 180–81
  - development of Internet in 140–41
  - employment rate in 281
  - entry, exit and turnover in 294, 295, 296, 298–300, 301–2
  - expenditure on mission-oriented R&D 66–7, 133, 135–44
  - expenditure on non-mission-oriented R&D 134, 135
  - firm size distribution in 291, 293–4, 301
  - funding sources for ESTD in 373
  - GDP growth 315
  - government funding for start-up firms in 182, 183
  - government role as coordinator in 66–7
  - ICT firms located in 303
  - percentage of population with university degree 82
  - procurement policies in 139
  - productivity differences between Europe and, *see* European technology gap
  - productivity indicators 115
  - publications in life sciences in 81, 96
  - R&D expenditure at US universities 81–4, 96, 128, 140
  - selection mechanism for federal research funding in 105–7
  - tax treatment of R&D in 177–8, 192
  - technology policy regarding pharmaceuticals in 12–15
  - variety-preserving restrictions in 22
  - venture capital industry in 183–5
  - world market shares in ICT sectors 303
- universities
  - central government spending on 145, 164
  - ESTD funding by 373
  - importance in Swiss public innovation policy 273
  - patenting and licensing by 15–16, 143, 154, 342, 353–4
  - place in national innovation system 108
  - proximity to 94, 96, 249, 253, 263, 265, 266
  - public support to, in Sweden 272
  - responsive to shifts in demand for skills 389–90
  - share of agency R&D 137, 138, 140
  - university degrees, percentage of population with 82
  - University of Munich 224
  - University of Sussex 224
  - Urban, G.L. 329
  - urban transport patterns 22
  - US Congress 155, 156
  - US Defense Advances Research Projects Agency (DARPA) 138, 141
  - US Department of Agriculture 136, 137

- US Department of Defense 135, 136, 137, 139, 141, 143, 144, 145  
 US Department of Energy 136, 137  
 US Department of Health and Human Services 136, 137, 139  
 US Government Accountability Office (GAO) 143, 148  
 US House of Representatives Science Committee 99  
 US–Japanese semiconductor trade agreement 403  
 US National Academy of Sciences (NAS) 142  
 US National Aeronautics and Space Administration 136, 137  
 US Patent Office 382  
 US Securities and Exchange Commission 187  
 US Senate 156, 157  
 US Small Business Act 305  
 US Small Business Administration 225  
 US Supreme Court 153  
 user-centered innovation 327–35, 358–9  
     case studies 328–30, 359  
     collaborative user-centered innovation 332–3, 359, 405  
     conditions favorable to 333, 339  
     policies to support 333–5, 341, 362–4  
     measurement of 330–32  
 user patents 330  
  
 vaccines 14, 210, 379  
 value added tax (VAT) 275  
 van Ark, B. 284, 285, 287, 288, 312  
 van der Ploeg, F. 312  
 van Pottelsberghe de la Potterie, B. 117, 187  
 Van Reenen, J. 187, 245, 316  
 ‘varieties of capitalism’ investigations 20  
 variety  
     trade-off between selection and 36–8  
     value associated with 21–2  
 Varmus, H. 155  
 Vega, M. 249  
 venture capital  
     combining strengths of market-based and bank-centered capital market systems 186  
     concentration of VC industry 186, 187  
     European venture capital industry 183, 185, 319  
     governance of firms by venture capitalists 27, 184, 185  
     ICT and nanotechnology driven by 128  
     in Israel 380, 381, 382, 384–5  
     Japanese venture capital industry 185–6  
     limitations of VC system 187  
     in Switzerland 274–5, 276  
     US venture capital industry 183–5, 373  
 Vergragt, P. 29  
 Verheul, H. 29  
 Vernon, R. 248  
 Veugelers, R. 221, 248, 251, 266, 312  
 vicious circles 40  
 vision 37, 42–3  
 Vivarelli, M. 221  
 von Hippel, E. 207, 328, 329, 330, 333, 337, 339, 354, 358, 359, 362, 405  
 Von Kalckreuth, U. 211  
 von Laue, Max 86, 88  
 Vu, K. 376  
  
 wages and salaries 171, 197, 384  
 Wal-Mart 375  
 Wallstein, S. 305  
 Walsh, J. 154  
 Walton, K.S. 174  
 Washington University 92  
 Watson, James 86, 89, 90  
 Weber, S. 353  
 Weeds, H. 211  
 Weinberg, A. 103  
 Weitzman, M. 392  
 Welch, I. 181, 187  
 Whited, T.M. 211  
 wholesale trade sector 286, 289, 293, 295, 300, 307, 316  
 Wikipedia 337, 338, 350  
 Wilkins, Maurice 89  
 Williams, J.C. 371  
 Williamson, O.E. 177  
 Wilson, D.S. 344



- Windows 363  
Winter, S. 7, 29, 35, 36, 39  
within-firm effect 297, 298, 299, 301  
women, labor market participation of  
268, 315  
World Economic Forum 272  
World Trade Organization (WTO)  
403  
World War II 12, 95, 145, 155  
Wright, G. 58  
Wright, P. 177  
Wyplosz, C. 309  
  
X-ray crystallography 86–90, 93, 127  
X-ray diffraction 86  
  
X-ray machine 85, 86  
  
Yamagishi, T. 351  
Yao, D.A. 174  
Yeaple, S.R. 117  
Yosha, O. 176–7  
Yozma program 380, 381  
  
Zanfei, A. 248  
Zantout, Z.Z. 174  
Zellner, C. 116  
Zerhouni, Elias 149, 150  
Zingales, L. 186  
Zinoecker, K. 107  
Zucker, L.G. 110, 120, 349

